
    
      This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low- to
      intermediate-grade (Grade 1 or Grade 2), well-differentiated NETs.

      The study will enroll 4 cohorts of varying NETs, as follows:

        -  Cohort A - NET of lung origin

        -  Cohort B - NET of small bowel origin

        -  Cohort C - NET of non-small bowel, non-pancreas, and non-lung origin

        -  Cohort D - NET of any origin (DDI substudy)

      All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days
      starting on Cycle 1 Day 1.
    
  